cyclic heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-14. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4 melanocortin receptor | Other melanocortin subtypes are also activated |
| Typical route in approved use | Subcutaneous injection | Single-use format in the marketed product |
| Elimination half-life | Roughly two to three hours | Short exposure supports as-needed use |
| Common adverse events | Nausea, flushing, headache | Generally transient but can be dose limiting |
| Main studied group | Premenopausal women with low desire | Controlled data outside this group are limited |
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
In 1979 Zaffaroni was awarded the Chemical Pioneer Award by the American Institute of Chemists In 1995, he received the National Medal of Technology from President Bill Clinton for his contributions to the pharmaceutical and biotechnology industries. In 2004, he was one of the recipients of the Winthrop-Sears Medal from the Chemical Heritage Foundation and The Chemists’ Club, with George Rosenkranz. In 2005 he received the Bower Award for Business Leadership from the Franklin Institute for his creation of new biochemical processes and drug delivery technologies. In 2005 he was awarded the Gregory Pincus Award from the Worcester Foundation. In 2006, he received the Biotechnology Heritage Award, from the Biotechnology Industry Organization (BIO) and the Chemical Heritage Foundation.
== γ-Lipotropin == γ-lipotropin is the amino-terminal peptide fragment of β-lipotropin. In humans, it has 56 amino acids. Gamma lipotropin is identical to the first 56 amino acid sequences of β-lipotropin. It can be cleaved to β-melanocyte stimulating hormone. In sheep, gamma-lipotropic hormone is a 58-amino-acid long pituitary polypeptide formed from the first 58 residues of beta-lipotropic hormone. The carboxyl-terminal of gamma-lipotropic hormone is identical to the structure of beta-melanophore-stimulating hormone.
One rationale was to amputate as close to the damage as possible to save as much of the remaining limb as possible. Others argued to amputate in a location that would fit a prosthetic the best. This was especially debated for lower leg amputation because a prosthetic would fit better if the leg was amputated closer to the knee. Paré is the first known surgeon to decide the location of an amputation based on how a prosthetic would fit on it in 1564.
Sources: en.wikipedia.org
== Origins == In 1927, Sakel, who had recently qualified as a medical doctor in Vienna and was working in a psychiatric clinic in Berlin, began to use low (sub-coma) doses of insulin to treat drug addicts and psychotics, and when one of the patients experienced improved mental clarity after having slipped into an accidental coma, Sakel reasoned the treatment might work for mentally ill patients. Having returned to Vienna, he treated schizophrenic patients with larger doses of insulin in order to deliberately produce coma and sometimes convulsions. Sakel made his results public in 1933, and his methods were soon taken up by other psychiatrists. Joseph Wortis, after seeing Sakel practice it in 1935, introduced it to the US. British psychiatrists from the Board of Control visited Vienna in 1935 and 1936, and by 1938, 31 hospitals in England and Wales had insulin treatment units. In 1936, Sakel moved to New York and promoted the use of insulin coma treatment in US psychiatric hospitals. By the late 1940s, the majority of psychiatric hospitals in the US were using insulin coma treatment.
=== Cosmetics === Some hair shampoos on the market include estrogens and placental extracts; others contain phytoestrogens. In 1998, there were case reports of four prepubescent African-American girls developing breasts after exposure to these shampoos. In 1993, the FDA determined that not all over-the-counter topically applied hormone-containing drug products for human use are generally recognized as safe and effective and are misbranded. An accompanying proposed rule deals with cosmetics, concluding that any use of natural estrogens in a cosmetic product makes the product an unapproved new drug and that any cosmetic using the term "hormone" in the text of its labeling or in its ingredient statement makes an implied drug claim, subjecting such a product to regulatory action. In addition to being considered misbranded drugs, products claiming to contain placental extract may also be deemed to be misbranded cosmetics if the extract has been prepared from placentas from which the hormones and other biologically active substances have been removed and the extracted substance consists principally of protein. The FDA recommends that this substance be identified by a name other than "placental extract" and describing its composition more accurately because consumers associate the name "placental extract" with a therapeutic use of some biological activity.
The United States military began executing airstrikes on vessels in the Caribbean Sea in September 2025, described by the administration of President Donald Trump as part of an effort to fight the flow of illicit drugs from Latin America to the US. In October, the strikes expanded to include vessels in the Eastern Pacific Ocean. The Trump administration has alleged, without producing public evidence, that the vessels were operated by groups it designated as narcoterrorists, including the Venezuelan organization Tren de Aragua and the Colombian far-left guerilla group National Liberation Army. As part of what was later unveiled as Operation Southern Spear, the US began deploying Navy warships and personnel to the Caribbean in mid-August. Trump announced on 2 September that the US Navy had carried out the first airstrike in the Caribbean on a boat from Venezuela, killing all 11 people aboard; he released a video of the incident, which Venezuelan sources said had occurred on 1 September. US officials said that this was a military operation against drug cartels in Latin America and that these military operations would continue. As of 19 September 2026, at least 234 people had been killed (including 17 who are missing and presumed dead) in at least 78 strikes on over 79 vessels and the US had made its first strike on a land target within Venezuela. On 12 June, Niño Guerrero, leader of Tren de Aragua, was killed in joint operation with the post-Maduro Venezuelan government.
Sources: en.wikipedia.org
The Solomon Islands-China security pact caused alarm in late 2022, as China could build military bases across the South Pacific. Biden sought to strengthen ties with Australia and New Zealand in the wake of the deal. In a September 2022 interview with 60 Minutes, Biden said that U.S. forces would defend Taiwan in the event of "an unprecedented attack" by the Chinese, which is in contrast to the long-standing U.S. policy of "strategic ambiguity" toward China and Taiwan. The September comments came after three previous comments by Biden that the U.S. would defend Taiwan in the event of a Chinese invasion. Amid increasing tension with China, Biden's administration has repeatedly walked back his statements and asserted that U.S. policy toward Taiwan has not changed. In late 2022, Biden issued several executive orders and federal rules designed to slow Chinese technological growth, and maintain U.S. leadership over computing, biotech, and clean energy. On February 4, 2023, Biden ordered the United States Air Force to shoot down a suspected Chinese surveillance balloon off the coast of South Carolina. The Chinese government denied that the balloon was a surveillance device, instead claiming it was a civilian airship that had blown off course. Secretary of State Antony Blinken postponed his planned visit to China as the incident further damaged U.S.-China relations. In May 2024, the Biden administration doubled tariffs on solar cells imported from China and more than tripled tariffs on lithium-ion electric vehicle batteries imported from China.
==== Niccolò Figà-Talamanca ==== Niccolò Figà-Talamanca, the secretary-general of the NGO No Peace Without Justice, was one of the original four suspects arrested in the case. On 14 December 2022, Figà-Talamanca was released from prison with an electronic bracelet to track his movements, but the Belgian federal prosecutor successfully appealed the order on 27 December 2022, so Figà-Talamanca went back to prison. Figà-Talamanca was released from prison without conditions by the investigative judge at a hearing on 3 February 2023. Figà-Talamanca's lawyer at the hearings was Barbara Huylebroek. According to a member of his family, Figà-Talamanca remains charged.
==== Hierarchical deterministic wallet ==== The hierarchical deterministic (HD) wallet was publicly described in BIP32. As a deterministic wallet, it derives keys from a single master root seed, but instead of having a single "chain" of key pairs, an HD wallet supports multiple independent key pair chains. This allows a single seed to be used to generate an entire tree of key pairs with a stratified structure.
Sources: en.wikipedia.org
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.
It means the product is taken shortly before anticipated activity instead of every day. This pattern reduces total exposure and shapes how safety monitoring is planned. It also means effects are expected to be temporary rather than cumulative.
Desire is assessed through validated self-report questionnaires, sometimes paired with event counts and a distress scale. These instruments capture subjective experience, so results depend on how participants interpret the questions. No laboratory marker currently substitutes for such reporting.
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.